Patents by Inventor Rudong Shan
Rudong Shan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10272081Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: GrantFiled: January 30, 2018Date of Patent: April 30, 2019Assignee: Aquinox Pharmaceuticals (Canada) Inc.Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
-
Publication number: 20180360828Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: January 30, 2018Publication date: December 20, 2018Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
-
Publication number: 20180161324Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: January 30, 2018Publication date: June 14, 2018Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
-
Patent number: 9937167Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: GrantFiled: December 6, 2016Date of Patent: April 10, 2018Assignee: Aquinox Pharmaceuticals (Canada) Inc.Inventors: Lloyd F. Mackenzie, Thomas B. Macrury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
-
Patent number: 9751894Abstract: Cephem compounds, pharmaceutically acceptable salts thereof, and methods of using same, wherein the compound has a bicyclic nitrogen-containing aromatic heterocyclic ring as the quaternary ammoniomethyl group at the 3-position and one or both of a terminal amidine residue (substituted or unsubstituted) attached to an aryl or a 5- or 6-membered heteroaryl group (substituted or unsubstituted) which is further attached through a spacer to the free N-atom of the quaternary nitrogen-containing bicyclic ring at the 3-side chain, or a terminal guanidine residue attached to an aryl or a 5- or 6-membered heteroaryl group (substituted or unsubstituted) which is further attached through a spacer to the free N-atom of the quaternary nitrogen-containing bicyclic ring at the 3-side chain.Type: GrantFiled: December 5, 2016Date of Patent: September 5, 2017Assignee: NAEJA-RGM PHARMACEUTICALS INC.Inventors: Samarendra Nath Maiti, Dai Quoc Nguyen, Andhe V. N. Reddy, Judy Yip, Chan Minh Ha, Rong Ling, Rudong Shan, Madhava Reddy Madala
-
Publication number: 20170224682Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: December 6, 2016Publication date: August 10, 2017Inventors: Lloyd F. MACKENZIE, Thomas B. MACRURY, Curtis HARWIG, David BOGUCKI, Jeffery R. RAYMOND, Jeremy D. PETTIGREW, Vladimir KHLEBNIKOV, Rudong SHAN
-
Publication number: 20170166587Abstract: Cephem compounds, pharmaceutically acceptable salts thereof, and methods of using same, wherein the compound has a bicyclic nitrogen-containing aromatic heterocyclic ring as the quaternary ammoniomethyl group at the 3-position and one or both of a terminal amidine residue (substituted or unsubstituted) attached to an aryl or a 5- or 6-membered heteroaryl group (substituted or unsubstituted) which is further attached through a spacer to the free N-atom of the quaternary nitrogen-containing bicyclic ring at the 3-side chain, or a terminal guanidine residue attached to an aryl or a 5- or 6-membered heteroaryl group (substituted or unsubstituted) which is further attached through a spacer to the free N-atom of the quaternary nitrogen-containing bicyclic ring at the 3-side chain.Type: ApplicationFiled: December 5, 2016Publication date: June 15, 2017Inventors: Samarendra Nath MAITI, Dai Quoc NGUYEN, Andhe V.N. REDDY, Judy YIP, Chan Minh HA, Rong LING, Rudong SHAN, Madhava Reddy MADALA
-
Patent number: 9540353Abstract: Compounds of formula (I): where, n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: GrantFiled: January 7, 2014Date of Patent: January 10, 2017Assignee: Aquinox Pharmaceuticals (Canada) Inc.Inventors: Lloyd F. Mackenzie, Thomas B. Macrury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
-
Publication number: 20160257671Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: January 7, 2014Publication date: September 8, 2016Inventors: Lloyd F. MACKENZIE, Thomas B. MACRURY, Curtis HARWIG, David BOGUCKI, Jeffery R. RAYMOND, Jeremy D. PETTIGREW, Vladimir KHLEBNIKOV, Rudong SHAN
-
Publication number: 20150336935Abstract: Compounds of formula (I): where, n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: January 7, 2014Publication date: November 26, 2015Inventors: Lloyd F. MACKENZIE, Thomas B. MACRURY, Curtis HARWIG, David BOGUCKI, Jeffery R. RAYMOND, Jeremy D. PETTIGREW, Vladimir KHLEBNIKOV, Rudong SHAN
-
Patent number: 8101605Abstract: Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: GrantFiled: December 3, 2010Date of Patent: January 24, 2012Assignee: Aquinox Pharmaceuticals Inc.Inventors: Lloyd Mackenzie, Tom MacRury, Curtis Harwig, Jeremy Pettigrew, Noor Aini Bhatti, Sam Place, Paul Bird, Vladimir Khlebnikov, Rudong Shan
-
Publication number: 20110136802Abstract: Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: December 3, 2010Publication date: June 9, 2011Applicant: Aquinox Pharmaceuticals Inc.Inventors: Lloyd Mackenzie, Tom MacRury, Curtis Harwig, Jeremy Pettigrew, Noor Aini Bhatti, Sam Place, Paul Bird, Vladimir Khlebnikov, Rudong Shan
-
Patent number: 5907047Abstract: This invention relates to a new biologically active compound as shown in formula (I) and its biologically active derivatives; whereas derivatives are produced by the reaction of formula (I) with nucleophiles.Type: GrantFiled: July 23, 1998Date of Patent: May 25, 1999Assignee: Boehringer Mannheim GmbHInventors: Fritz Hansske, Olov Sterner, Marc Satadler, Heidrun Anke, Liesel Dorge, Rudong Shan
-
Patent number: RE48097Abstract: Cephem compounds, pharmaceutically acceptable salts thereof, and methods of using same, wherein the compound has a bicyclic nitrogen-containing aromatic heterocyclic ring as the quaternary ammoniomethyl group at the 3-position and one or both of a terminal amidine residue (substituted or unsubstituted) attached to an aryl or a 5- or 6-membered heteroaryl group (substituted or unsubstituted) which is further attached through a spacer to the free N-atom of the quaternary nitrogen-containing bicyclic ring at the 3-side chain, or a terminal guanidine residue attached to an aryl or a 5- or 6-membered heteroaryl group (substituted or unsubstituted) which is further attached through a spacer to the free N-atom of the quaternary nitrogen-containing bicyclic ring at the 3-side chain.Type: GrantFiled: December 19, 2018Date of Patent: July 14, 2020Assignee: NAEJA-RGM PHARMACEUTICALS ULCInventors: Samarendra Nath Maiti, Dai Quoc Nguyen, Andhe V. N. Reddy, Judy Yip, Chan Minh Ha, Rong Ling, Rudong Shan, Madhava Reddy Madala